Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.

Authors: Seth A Ettenberg, Olga Charlat, Michael P Daley, Shanming Liu, Karen J Vincent, Darrin D Stuart, Alwin G Schuller, Jing Yuan, Beatriz Ospina, John Green, Qunyan Yu, Renee Walsh, Sharon Li, Rita Schmitz, Holger Heine, Sanela Bilic, Lance Ostrom, Rebecca Mosher, K Felix Hartlepp, Zhenping Zhu, Stephen Fawell, Yung-Mae Yao, David Stover, Peter M Finan, Jeffery A Porter, William R Sellers, Ingo M Klagge, Feng Cong
Proc Natl Acad Sci U S A 2010 Aug 16;107(35):15473-8. Epub 2010 Aug 16.
Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
August 2010

Disregulated Wnt/beta-catenin signaling has been linked to various human diseases, including cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in cancers. LRP5 and LRP6 are closely related membrane coreceptors for Wnt proteins. Using a phage-display library, we identified anti-LRP6 antibodies that either inhibit or enhance Wnt signaling. Two classes of LRP6 antagonistic antibodies were discovered: one class specifically inhibits Wnt proteins represented by Wnt1, whereas the second class specifically inhibits Wnt proteins represented by Wnt3a. Epitope-mapping experiments indicated that Wnt1 class-specific antibodies bind to the first propeller and Wnt3a class-specific antibodies bind to the third propeller of LRP6, suggesting that Wnt1- and Wnt3a-class proteins interact with distinct LRP6 propeller domains. This conclusion is further supported by the structural functional analysis of LRP5/6 and the finding that the Wnt antagonist Sclerostin interacts with the first propeller of LRP5/6 and preferentially inhibits the Wnt1-class proteins. We also show that Wnt1 or Wnt3a class-specific anti-LRP6 antibodies specifically block growth of MMTV-Wnt1 or MMTV-Wnt3 xenografts in vivo. Therapeutic application of these antibodies could be limited without knowing the type of Wnt proteins expressed in cancers. This is further complicated by our finding that bivalent LRP6 antibodies sensitize cells to the nonblocked class of Wnt proteins. The generation of a biparatopic LRP6 antibody blocks both Wnt1- and Wnt3a-mediated signaling without showing agonistic activity. Our studies provide insights into Wnt-induced LRP5/6 activation and show the potential utility of LRP6 antibodies in Wnt-driven cancer.